Literature DB >> 17899230

Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia.

D Horn1, D Neofytos, J Fishman, W Steinbach, E Anaisie, K A Marr, M Pfaller, A Olyaei.   

Abstract

Candidemia is an increasing complication of the care of complex patients. Adherence to Infectious Diseases Society of America (IDSA) guidelines for the treatment of candidemia was investigated to assess the impact of compliance on outcomes of therapy. Data on the epidemiology, diagnosis, and treatment of patients with invasive fungal infections (IFIs) was extracted from the PATH Alliance registry, a prospective, multicenter, observational database of invasive fungal infections. Patients with proven candidemia were evaluated for adherence to the IDSA guidelines in terms of choice, dosage, and duration of antifungal therapy. Removal of central venous catheters and time to treatment initiation were assessed. Four-week survival data were compared. Of the 418 patients with candidemia who were included in the study, 361 patients with the necessary data sets were identified, of whom 262 (72.6%) were treated within the IDSA guidelines for the treatment of candidemia (IDSA group); the remaining 99 (27.4%) patients received treatment different from the guidelines (non-IDSA group). Kaplan-Meier (KM) survival analysis for patients in the IDSA and non-IDSA group showed mortality rates of 21.9 and 13.6%, respectively; the difference between the two groups was not statistically significant (P = 0.093). Following the exclusion of patients requiring mechanical ventilation or acute cardiac support, the modified survival KM curves were similar between the two groups. Significantly more patients in the IDSA group required mechanical ventilation and tunneled central catheters, had a concomitant IFI, and received caspofungin. The duration of treatment and inappropriate dosing did not appear to have had a significant impact on survival. Most of the deviations from IDSA guidelines were due to the inappropriate duration and dosing of therapy. No significant difference in mortality was noted between the IDSA and non-IDSA groups. The basis of these differences merit further study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899230     DOI: 10.1007/s10096-007-0383-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  Guidelines for treatment of candidiasis.

Authors:  Peter G Pappas; John H Rex; Jack D Sobel; Scott G Filler; William E Dismukes; Thomas J Walsh; John E Edwards
Journal:  Clin Infect Dis       Date:  2003-12-19       Impact factor: 9.079

2.  The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.

Authors:  Theoklis E Zaoutis; Jesse Argon; Jaclyn Chu; Jesse A Berlin; Thomas J Walsh; Chris Feudtner
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

3.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

Authors:  J H Rex; T J Walsh; J D Sobel; S G Filler; P G Pappas; W E Dismukes; J E Edwards
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

4.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

5.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

6.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

Authors:  B J Kullberg; J D Sobel; M Ruhnke; P G Pappas; C Viscoli; J H Rex; J D Cleary; E Rubinstein; L W P Church; J M Brown; H T Schlamm; I T Oborska; F Hilton; M R Hodges
Journal:  Lancet       Date:  2005 Oct 22-28       Impact factor: 79.321

Review 7.  Invasive Candida infections: the changing epidemiology.

Authors:  Kieren A Marr
Journal:  Oncology (Williston Park)       Date:  2004-12       Impact factor: 2.990

8.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

Authors:  M B Edmond; S E Wallace; D K McClish; M A Pfaller; R N Jones; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

9.  Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines.

Authors:  Mukesh Patel; Danielle F Kunz; Vivek M Trivedi; Marga G Jones; Stephen A Moser; John W Baddley
Journal:  Diagn Microbiol Infect Dis       Date:  2005-05       Impact factor: 2.803

10.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

View more
  4 in total

1.  Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance® registry.

Authors:  D Neofytos; S Huprikar; A Reboli; M Schuster; N Azie; B Franks; D Horn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-02       Impact factor: 3.267

Review 2.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

3.  Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.

Authors:  Dionissios Neofytos; Edina Avdic; Anna-Pelagia Magiorakos
Journal:  Drug Healthc Patient Saf       Date:  2010-04-20

4.  Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study.

Authors:  Tafireyi Marukutira; Shirish Huprikar; Nkechi Azie; Shun-Ping Quan; Herwig-Ulf Meier-Kriesche; David L Horn
Journal:  HIV AIDS (Auckl)       Date:  2014-03-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.